As filed with the Securities and Exchange Commission on June 26, 2007

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

POST-EFFECTIVE AMENDMENT NO. 2 ON FORM S-8 TO
FORM S-4 REGISTRATION STATEMENT NO. 333-88835

 

Under

The Securities Act of 1933

 

 

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

 

One MedImmune Way

Gaithersburg, MD 20878

(301) 398-0000

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

1999 Incentive Compensation Plan

1987 Incentive Stock Option Plan

1987 Non-Statutory Stock Option Plan

1991 Special Non-Statutory Stock Option Plan

1987 Special Non-Statutory Stock Option Plan

1992 Stock Option Plan

1996 Non-Employee Directors Stock Option Plan

Non-Executive Stock Option Plan

of U.S. Bioscience, Inc.

(Full Titles of the Plans)

 

David M. Mott

Chief Executive Officer, President

MedImmune, Inc.

One MedImmune Way

Gaithersburg, MD 20878

(301) 398-0000

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

 

 

 

DEREGISTRATION OF UNSOLD SECURITIES

This Post-Effective Amendment No. 2 relates to the following Registration Statement on Form S-4 of MedImmune, Inc. (the “Company”) (the “Registration Statement”):

File No. 333-88835, which was filed with the Securities and Exchange Commission (the “SEC”) and became effective on October 21, 1999, as amended by Post-Effective Amendment No. 1 pertaining to the registration of 752,433 shares of common stock, par value $0.01 per share of the Company (“Common Stock”), which was filed with the SEC and became effective on November 23, 1999.

On April 22, 2007, the Company, AstraZeneca PLC, a public limited company incorporated under the laws of England and Wales (“Parent”), and AstraZeneca Biopharmaceuticals Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Purchaser”), entered into an Agreement and Plan of Merger pursuant to which Purchaser merged with and into the Company, with the Company surviving as an indirect wholly owned subsidiary of Parent (the “Merger”).  The Merger became effective on June 18, 2007 as a result of the filing of a certificate of ownership and merger effectuating the Merger with the Secretary of State of the State of Delaware.

As a result of the Merger, the offering pursuant to the Registration Statement has been terminated.  In accordance with undertakings made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company registered but unsold under the Registration Statement.

 

 

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, MedImmune, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 2 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Gaithersburg, State of Maryland, on June 26, 2007.

		MEDIMMUNE, INC.
		By:		/s/ David M. Mott
		Name:		David M. Mott
		Title:		Chief Executive Officer and President

 

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 has been signed by the following persons, in the capacities indicated, as of June 26, 2007.

	Signature				Title
/s/ David M. Mott
Name: David M. Mott				Chief Executive Officer and President
/s/ Lota S. Zoth
Name:Lota S. Zoth				Chief Financial Officer and Senior Vice President
/s/ Glenn M. Engelmann
Name: Glenn M. Engelmann				Director
/s/ Shaun F. Grady
Name: Shaun F. Grady				Director
/s/ Christopher R. W. Petty
Name: Christopher R. W. Petty				Director

 

 

3